Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2179400 | 0.89 | KDM4E (0.52) | GAAKDM4ELMNAKEAP1SMN1; SMN2 | |
| SCHEMBL21952349 | 0.87 | GAA (0.54) | GAAKDM4ELMNAKEAP1SMN1; SMN2 | |
| SCHEMBL21994880 | 0.87 | GAA (0.54) | GAAKDM4ELMNAKEAP1SMN1; SMN2 | |
| SCHEMBL14796019 | 0.85 | L3MBTL1 (0.47) | GAAKDM4ELMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL18162805 | 0.84 | GAA (0.51) | GAAKDM4ELMNAKEAP1SMN1; SMN2 | |
| SCHEMBL14795584 | 0.84 | L3MBTL1 (0.50) | GAALMNASMN1; SMN2ALDH1A1ANPEP | |
| SCHEMBL2181054 | 0.82 | PAOX (0.47) | GAAKDM4ELMNASMN1; SMN2RAB9A | |
| SCHEMBL18159725 | 0.80 | GAA (0.48) | GAAKDM4ELMNAKEAP1SMN1; SMN2 | |
| SCHEMBL18162791 | 0.80 | GAA (0.51) | GAAKDM4ELMNAKEAP1SMN1; SMN2 | |
| SCHEMBL30088669 | 0.80 | GAA (0.55) | GAAKDM4ELMNAKEAP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3929203-A1 | DERIVATIVES OF AMPHOTERICIN B | Sfunga Therapeutics, Inc. (US) | 2021-12-29 | — | — | EP | disclosed |
| WO-2016168568-A1 | DERIVATIVES OF AMPHOTERICIN B | Revolution Medicines, Inc. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-8173808-B2 | Substituted naphthalenyl-pyrimidine compounds | ARQULE, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110166137-A1 | Substituted Naphthalenyl-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166137-A1 | Substituted Naphthalenyl-Pyrimidine Compounds | DPYD, TP53, TYMP | GAA 823/4885KDM4E 2457/4885LMNA 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.